CD79A and systemic lupus erythematosus: The low GLRX2 expression group exhibited an activation trend in several biological processes and diseases, including asthma, drug metabolism (via the cytochrome P450 pathway), IgA production in the intestinal immune network, xenobiotic metabolism (via the cytochrome P450 pathway), systemic lupus erythematosus, and viral myocarditis.